This post was originally published on Forbes Middle East
US-based pharmaceutical giant Pfizer raised its full-year guidance after reporting a 3% rise in revenue for the second quarter of 2024 to $13.3 billion, driven by strong sales of its heart disease drug and newly acquired cancer treatments.
…